Form 4: Evoke Pharma Executive Acquires 11,000 Stock Options

Marilyn R. Carlson, Chief Medical Officer of Evoke Pharma, acquired 11,000 stock options on January 28, 2025, according to a Form 4 filing.

Summary

• Marilyn R. Carlson, the Chief Medical Officer of Evoke Pharma, Inc. (EVOK), filed a Form 4 with the SEC.
• The filing reports the acquisition of 11,000 stock options on January 28, 2025.
• The exercise price of these options is $4.45.
• The options vest monthly over three years, starting January 28, 2025, and expire on January 27, 2035.
• Following the transaction, Carlson directly owns 11,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock option grants, which can be seen as a positive sign of executive alignment with company goals, but doesn't provide enough information to be strongly positive.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of Evoke Pharma's securities by one of its executives.

Stakeholder Impact

• The acquisition of stock options by a key executive could positively influence shareholder sentiment.

Key Dates

Keywords

Evoke Pharma, Stock Options, Form 4, SEC Filing, Marilyn R. Carlson, Chief Medical Officer, Beneficial Ownership, EVOK